Artykuły w czasopismach na temat „Hemolytic uremic syndrome Prevention”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Hemolytic uremic syndrome Prevention”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Yoshiya, Kunihiko, Kouichi Nakanishi, Seiko Itoh, Kazumoto Iijima, Norishige Yoshikawa, Hajime Nakamura, Tae Takeda i Kazuhiro Kobayashi. "Etiology and prevention of hemolytic uremic syndrome". Nihon Shoni Jinzobyo Gakkai Zasshi 7, nr 2 (1994): 161–63. http://dx.doi.org/10.3165/jjpn.7.161.
Pełny tekst źródłaAfshar-Kharghan, Vahid. "Atypical hemolytic uremic syndrome". Hematology 2016, nr 1 (2.12.2016): 217–25. http://dx.doi.org/10.1182/asheducation-2016.1.217.
Pełny tekst źródłaGoldwater, Paul N. "Treatment and prevention of enterohemorrhagicEscherichia coliinfection and hemolytic uremic syndrome". Expert Review of Anti-infective Therapy 5, nr 4 (sierpień 2007): 653–63. http://dx.doi.org/10.1586/14787210.5.4.653.
Pełny tekst źródłaHaslam, David B. "Molecular Decoys: Novel Approaches to the Prevention of Hemolytic Uremic Syndrome". Pediatric Research 48, nr 3 (wrzesień 2000): 267–68. http://dx.doi.org/10.1203/00006450-200009000-00001.
Pełny tekst źródłaJoseph, Adrien, Aurélie Cointe, Patricia Mariani Kurkdjian, Cédric Rafat i Alexandre Hertig. "Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review". Toxins 12, nr 2 (21.01.2020): 67. http://dx.doi.org/10.3390/toxins12020067.
Pełny tekst źródłaTARR, PHILLIP I. "Escherichia coli O157: H7: Overview of Clinical and Epidemiological Issues". Journal of Food Protection 57, nr 7 (1.07.1994): 632–37. http://dx.doi.org/10.4315/0362-028x-57.7.632.
Pełny tekst źródłaDavin, Jean-Claude, Charles Majoie, Jaap Groothoff, Valentina Gracchi, Antonia Bouts, Timothy H. J. Goodship i Chantal Loirat. "Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation". Pediatric Nephrology 26, nr 1 (24.07.2010): 155–57. http://dx.doi.org/10.1007/s00467-010-1608-9.
Pełny tekst źródłaNuernberger, Jens, Oliver Witzke, Russell P. Rother, Thomas Philipp, Udo Vester, Hideo Baba, Lothar Bernd Zimmerhackl i Andreas Kribben. "Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab." Blood 112, nr 11 (16.11.2008): 2294. http://dx.doi.org/10.1182/blood.v112.11.2294.2294.
Pełny tekst źródłaNoris, Marina, i Giuseppe Remuzzi. "Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation". Current Opinion in Nephrology and Hypertension 22, nr 6 (listopad 2013): 704–12. http://dx.doi.org/10.1097/mnh.0b013e328365b3fe.
Pełny tekst źródłaAvila Bernabeu, Ana Isabel, Teresa Cavero Escribano i Mercedes Cao Vilarino. "Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era". Nephron 144, nr 11 (2020): 537–49. http://dx.doi.org/10.1159/000508920.
Pełny tekst źródłaWinchester, Mae-Lan, Ryan Platzbecker, Megan McMahon i Marc Parrish. "Eculizumab Maintenance and the Prevention of Atypical Hemolytic Uremic Syndrome Relapse During Pregnancy: A Case Report". Journal of Medical Cases 10, nr 12 (2019): 343–44. http://dx.doi.org/10.14740/jmc3397.
Pełny tekst źródłaGiordano, Mario, Maria Elisabetta Baldassarre, Viviana Palmieri, Diletta D. Torres, Vincenza Carbone, Luisa Santangelo, Federico Gentile i in. "Management of STEC Gastroenteritis: Is There a Role for Probiotics?" International Journal of Environmental Research and Public Health 16, nr 9 (12.05.2019): 1649. http://dx.doi.org/10.3390/ijerph16091649.
Pełny tekst źródłaVallance, Bruce A., Crystal Chan, Marilyn L. Robertson i B. Brett Finlay. "Enteropathogenic and EnterohemorrhagicEscherichia coliInfections: Emerging Themes in Pathogenesis and Prevention". Canadian Journal of Gastroenterology 16, nr 11 (2002): 771–78. http://dx.doi.org/10.1155/2002/410980.
Pełny tekst źródłaRobitaille, Pierre, Marie-José Clermont, Aïcha Mérouani, Véronique Phan i Anne-Laure Lapeyraque. "Hemolytic Uremic Syndrome: Late Renal Injury and Changing Incidence—A Single Centre Experience in Canada". Scientifica 2012 (2012): 1–7. http://dx.doi.org/10.6064/2012/341860.
Pełny tekst źródłaGonzalez Suarez, Maria L., Charat Thongprayoon, Michael A. Mao, Napat Leeaphorn, Tarun Bathini i Wisit Cheungpasitporn. "Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis". Journal of Clinical Medicine 8, nr 7 (27.06.2019): 919. http://dx.doi.org/10.3390/jcm8070919.
Pełny tekst źródłaBaiko, S. V. "FIRST EXPERIENCE OF USING THE BIOSIMILAR OF ORIGINAL ECULIZUMAB FOR PREVENTION OF ATYPICAL HEMOLYTIC-UREMIC SYNDROME RECURRENCE AFTER RENAL TRANSPLANTATION IN A CHILD". Pediatria. Journal named after G.N. Speransky 100, nr 1 (15.02.2021): 293–96. http://dx.doi.org/10.24110/0031-403x-2021-100-1-293-296.
Pełny tekst źródłaLuz, Daniela, Maria Amaral, Flavia Sacerdoti, Alan Bernal, Wagner Quintilio, Ana Moro, Marina Palermo, Cristina Ibarra i Roxane Piazza. "Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo". Toxins 10, nr 12 (2.12.2018): 508. http://dx.doi.org/10.3390/toxins10120508.
Pełny tekst źródłaAhn, Christina K., Eileen Klein i Phillip I. Tarr. "Editorial Commentary:Isolation of Patients Acutely Infected withEscherichia coliO157:H7: Low‐Tech, Highly Effective Prevention of Hemolytic Uremic Syndrome". Clinical Infectious Diseases 46, nr 8 (15.04.2008): 1197–99. http://dx.doi.org/10.1086/587664.
Pełny tekst źródłaRiddell, Amy, Tim Goodship i Coralie Bingham. "Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab". Clinical Nephrology 86, nr 10 (1.10.2016): 200–202. http://dx.doi.org/10.5414/cn108808.
Pełny tekst źródłaPickering, Matthew C., Elena Goicoechea de Jorge, Rubén Martinez-Barricarte, Sergio Recalde, Alfredo Garcia-Layana, Kirsten L. Rose, Jill Moss i in. "Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains". Journal of Experimental Medicine 204, nr 6 (21.05.2007): 1249–56. http://dx.doi.org/10.1084/jem.20070301.
Pełny tekst źródłaMenne, Jan, Yahsou Delmas, Fadi Fakhouri, John F. Kincaid, Christoph Licht, Enrico E. Minetti, Chris Mix i in. "SO050LONG-TERM FOLLOW-UP STUDY OF ECULIZUMAB FOR PREVENTION OF THROMBOTIC MICROANGIOPATHY IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME". Nephrology Dialysis Transplantation 31, suppl_1 (maj 2016): i84. http://dx.doi.org/10.1093/ndt/gfw153.02.
Pełny tekst źródłaLüth, Stefan, Thorben W. Fründt, Thomas Rösch, Christoph Schlee i Ansgar W. Lohse. "Prevention of Hemolytic Uremic Syndrome With Daily Bowel Lavage in Patients With Shiga Toxin–Producing EnterohemorrhagicEscherichia coliO104:H4 Infection". JAMA Internal Medicine 174, nr 6 (1.06.2014): 1003. http://dx.doi.org/10.1001/jamainternmed.2014.1175.
Pełny tekst źródłaSheth, Kruti, Raffaele Girlanda i Catherine Broome. "Long-Term Management of Atypical Hemolytic Uremic Syndrome after Non-Renal Solid Organ Transplantation with Eculizumab". Blood 126, nr 23 (3.12.2015): 3466. http://dx.doi.org/10.1182/blood.v126.23.3466.3466.
Pełny tekst źródłaLukyanenko, Valeriy, Irina Malyukova, Ann Hubbard, Michael Delannoy, Edgar Boedeker, Chengru Zhu, Liudmila Cebotaru i Olga Kovbasnjuk. "EnterohemorrhagicEscherichia coliinfection stimulates Shiga toxin 1 macropinocytosis and transcytosis across intestinal epithelial cells". American Journal of Physiology-Cell Physiology 301, nr 5 (listopad 2011): C1140—C1149. http://dx.doi.org/10.1152/ajpcell.00036.2011.
Pełny tekst źródłaProkopenko, E. I., S. A. Pasov, A. V. Vatazin, A. Ya Tsalman, T. E. Pankratenko i G. A. Generalova. "Kidney transplantation using complement inhibitor in a patient suffering from atypical hemolytic-uremic syndrome associated with factor H antibodies: successful prevention of recurrence of the underlying disease". Russian Journal of Transplantology and Artificial Organs 22, nr 2 (12.07.2020): 132–38. http://dx.doi.org/10.15825/1995-1191-2020-2-132-138.
Pełny tekst źródłaZhu, George. "Retrospective Survey on the Outcome of 36 Diverse Cases of Anemia". Clinical Oncology Research and Reports 1, nr 1 (24.07.2020): 01–07. http://dx.doi.org/10.31579/2693-4787/004.
Pełny tekst źródłaLang, Elisabeth, i Florian Lang. "Triggers, Inhibitors, Mechanisms, and Significance of Eryptosis: The Suicidal Erythrocyte Death". BioMed Research International 2015 (2015): 1–16. http://dx.doi.org/10.1155/2015/513518.
Pełny tekst źródłaKallianpur, Asha R., Yuki Bradford, Rajal K. Mody, Katie N. Garman, Nicole Comstock, Sarah L. Lathrop, Carol Lyons i in. "Genetic Susceptibility to Postdiarrheal Hemolytic-Uremic Syndrome After Shiga Toxin–Producing Escherichia coli Infection: A Centers for Disease Control and Prevention FoodNet Study". Journal of Infectious Diseases 217, nr 6 (6.12.2017): 1000–1010. http://dx.doi.org/10.1093/infdis/jix633.
Pełny tekst źródłaFRENZEN, PAUL D., ALISON DRAKE i FREDERICK J. ANGULO. "Economic Cost of Illness Due to Escherichia coli O157 Infections in the United States". Journal of Food Protection 68, nr 12 (1.12.2005): 2623–30. http://dx.doi.org/10.4315/0362-028x-68.12.2623.
Pełny tekst źródłaTanaka, Kazuki, Naoya Fujita i Satoshi Hibino. "Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases". CEN Case Reports 9, nr 3 (2.04.2020): 247–51. http://dx.doi.org/10.1007/s13730-020-00465-x.
Pełny tekst źródłaPaton, Adrienne W., Renato Morona i James C. Paton. "Neutralization of Shiga Toxins Stx1, Stx2c, and Stx2e by Recombinant Bacteria Expressing Mimics of Globotriose and Globotetraose". Infection and Immunity 69, nr 3 (1.03.2001): 1967–70. http://dx.doi.org/10.1128/iai.69.3.1967-1970.2001.
Pełny tekst źródłaSheoran, Abhineet S., Susan Chapman, Pradeep Singh, Arthur Donohue-Rolfe i Saul Tzipori. "Stx2-Specific Human Monoclonal Antibodies Protect Mice against Lethal Infection with Escherichia coli Expressing Stx2 Variants". Infection and Immunity 71, nr 6 (czerwiec 2003): 3125–30. http://dx.doi.org/10.1128/iai.71.6.3125-3130.2003.
Pełny tekst źródłaAmorim, Jaime H., Monica R. Jesus, Wilson B. Luiz, Bruna F. M. M. Porchia, Rita C. C. Ferreira, Esteban G. Servat, Pablo D. Ghiringhelli, Luis C. S. Ferreira i Leticia V. Bentancor. "Role of bacteriophages in STEC infections: new implications for the design of prophylactic and treatment approaches". F1000Research 3 (18.03.2014): 74. http://dx.doi.org/10.12688/f1000research.3718.1.
Pełny tekst źródłaErsoy Dursun, F., G. Yesil, G. Sasak i H. Dursin. "Familial atypical hemolytic uremic syndrome with positive p.S1191L (c.3572C>T) mutation on the CFH gene: A single-center experience". Balkan Journal of Medical Genetics 24, nr 1 (1.06.2021): 81–88. http://dx.doi.org/10.2478/bjmg-2021-0007.
Pełny tekst źródłaLópez, Eduardo L., Maria M. Contrini, Eduardo Glatstein, Silvia González Ayala, Roberto Santoro, Daniel Allende, Gustavo Ezcurra i in. "Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody, against Shiga-Like Toxin 2 in Healthy Adults and in Pediatric Patients Infected with Shiga-Like Toxin-Producing Escherichia coli". Antimicrobial Agents and Chemotherapy 54, nr 1 (12.10.2009): 239–43. http://dx.doi.org/10.1128/aac.00343-09.
Pełny tekst źródłaRowe, Peter C., Ruth Milner, Elaine Orrbine, Terry P. Klassen, Paul G. Goodyer, Andrew M. MacKenzie, George A. Wells i in. "A PHASE II RANDOMIZED CONTROLLED TRIAL OF SYNSORB-PK FOR THE PREVENTION OF HEMOLYTIC UREMIC SYNDROME IN CHILDREN WITH VEROTOXIN-PRODUCING E. COLI (VTEC) GASTROENTERITIS. † 1684". Pediatric Research 41 (kwiecień 1997): 283. http://dx.doi.org/10.1203/00006450-199704001-01703.
Pełny tekst źródłaPellino, Christine A., Sayali S. Karve, Suman Pradhan i Alison A. Weiss. "AB5Preassembly Is Not Required for Shiga Toxin Activity". Journal of Bacteriology 198, nr 11 (21.03.2016): 1621–30. http://dx.doi.org/10.1128/jb.00918-15.
Pełny tekst źródłaBozio, Catherine H., Cheryl Isenhour i Lucy A. McNamara. "Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States". PLOS ONE 15, nr 11 (12.11.2020): e0241989. http://dx.doi.org/10.1371/journal.pone.0241989.
Pełny tekst źródłaArmstrong, G. D., P. C. Rowe, P. Goodyer, E. Orrbine, T. P. Klassen, G. Wells, A. MacKenzie i in. "A Phase I Study of Chemically Synthesized Verotoxin (Shiga-like Toxin) Pk-Trisaccharide Receptors Attached to Chromosorb for Preventing Hemolytic-Uremic Syndrome". Journal of Infectious Diseases 171, nr 4 (1.04.1995): 1042–45. http://dx.doi.org/10.1093/infdis/171.4.1042.
Pełny tekst źródłaKovbasnjuk, Olga, Michael Edidin i Mark Donowitz. "Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells". Journal of Cell Science 114, nr 22 (15.11.2001): 4025–31. http://dx.doi.org/10.1242/jcs.114.22.4025.
Pełny tekst źródłaKarmali, M. A. "Infection by verocytotoxin-producing Escherichia coli." Clinical Microbiology Reviews 2, nr 1 (styczeń 1989): 15–38. http://dx.doi.org/10.1128/cmr.2.1.15.
Pełny tekst źródłaLi, Yuling, Elizabeth Frey, Andrew M. R. Mackenzie i B. Brett Finlay. "Human Response to Escherichia coliO157:H7 Infection: Antibodies to Secreted Virulence Factors". Infection and Immunity 68, nr 9 (1.09.2000): 5090–95. http://dx.doi.org/10.1128/iai.68.9.5090-5095.2000.
Pełny tekst źródłaYu, Jia, Xuan Yuan, Hang Chen, Shruti Chaturvedi, Evan M. Braunstein i Robert A. Brodsky. "Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition". Blood 136, nr 18 (29.10.2020): 2080–89. http://dx.doi.org/10.1182/blood.2020008248.
Pełny tekst źródłaSHARAPOV, UMID M., ARTHUR M. WENDEL, JEFFREY P. DAVIS, WILLIAM E. KEENE, JEFFREY FARRAR, SAMIR SODHA, EIJA HYYTIA-TREES i in. "Multistate Outbreak of Escherichia coli O157:H7 Infections Associated with Consumption of Fresh Spinach: United States, 2006". Journal of Food Protection 79, nr 12 (1.12.2016): 2024–30. http://dx.doi.org/10.4315/0362-028x.jfp-15-556.
Pełny tekst źródłaSvetoch, E. A., I. A. Dyatlov, N. N. Kartsev, B. V. Eruslanov, M. E. Kanashenko i N. K. Fursova. "Development of candidate vaccines against infection caused by shiga-toxin producing Escherichia coli. Part 2". Bacteriology 5, nr 3 (2020): 47–59. http://dx.doi.org/10.20953/2500-1027-2020-3-47-59.
Pełny tekst źródłaTinoco, I., A. Jarrell, L. Correa, J. Bissler, J. DeVincenzo, Ivan Tinoco, Amber Jarrell, Lauren Correa, John J. Bissler i John P. DeVincenzo. "#92: What Is the Optimal Management of Patients Immunosuppressed with the Anti-compliment Monoclonal Antibody, Eculizumab? A Case Report and Review". Journal of the Pediatric Infectious Diseases Society 10, Supplement_1 (1.03.2021): S12. http://dx.doi.org/10.1093/jpids/piaa170.034.
Pełny tekst źródłaKrautz-Peterson, Greice, Susan Chapman-Bonofiglio, Karen Boisvert, Hanping Feng, Ira M. Herman, Saul Tzipori i Abhineet S. Sheoran. "Intracellular Neutralization of Shiga Toxin 2 by an A Subunit-Specific Human Monoclonal Antibody". Infection and Immunity 76, nr 5 (19.02.2008): 1931–39. http://dx.doi.org/10.1128/iai.01282-07.
Pełny tekst źródłaLAINE, ELLEN SWANSON, JONI M. SCHEFTEL, DAVID J. BOXRUD, KEVIN J. VOUGHT, RICHARD N. DANILA, KEVIN M. ELFERING i KIRK E. SMITH. "Outbreak of Escherichia coli O157:H7 Infections Associated with Nonintact Blade-Tenderized Frozen Steaks Sold by Door-to-Door Vendors". Journal of Food Protection 68, nr 6 (1.06.2005): 1198–202. http://dx.doi.org/10.4315/0362-028x-68.6.1198.
Pełny tekst źródłaMukherjee, Jean, Kerry Chios, Dianne Fishwild, Deborah Hudson, Susan O'Donnell, Stephen M. Rich, Arthur Donohue-Rolfe i Saul Tzipori. "Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection". Infection and Immunity 70, nr 2 (luty 2002): 612–19. http://dx.doi.org/10.1128/iai.70.2.612-619.2002.
Pełny tekst źródłaMelton-Celsa, Angela R., H. M. Carvalho, Claire Thuning-Roberson i A. D. O'Brien. "Protective Efficacy and Pharmacokinetics of Human/Mouse Chimeric Anti-Stx1 and Anti-Stx2 Antibodies in Mice". Clinical and Vaccine Immunology 22, nr 4 (25.02.2015): 448–55. http://dx.doi.org/10.1128/cvi.00022-15.
Pełny tekst źródła